Sentinel lymph node biopsy in vulvar cancer: a pilot study.

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Pathology

Background:

• Vulvar cancer management often involves extensive lymphadenectomy.
• Sentinel lymph node biopsy (SLNB) offers a less invasive alternative for staging vulvar cancer.
• Assessing the feasibility, efficacy, and accuracy of SLNB in vulvar cancer is crucial.

Purpose of the Study:

• To evaluate the feasibility, efficacy, and accuracy of the sentinel lymph node biopsy (SLNB) procedure in patients with early-stage vulvar cancer.
• To determine the detection rate and accuracy of SLNB in identifying lymph node metastasis.
• To assess the safety and potential of SLNB as a diagnostic tool in vulvar cancer staging.

Main Methods:

• A pilot study involving 17 patients with clinical Stages I and II vulvar cancer.
• Patients underwent sentinel lymph node (SLN) detection followed by complete inguinal-femoral lymphadenectomy.
• Demographic, surgical, and pathological data were collected and reviewed.

Main Results:

• The overall detection rate for the sentinel lymph node was 88.2% (15 out of 17 patients).
• Nineteen lymph nodes were positive for metastasis, with a median of five sentinel nodes identified per patient.
• SLNB accurately identified nodal status, with one patient having positive lymph nodes despite a non-detectable sentinel node.

Conclusions:

• Sentinel lymph node biopsy (SLNB) is a feasible and safe procedure for patients with vulvar cancer.
• The study indicates SLNB's potential for accurate staging in early-stage vulvar cancer.
• Further research and new guidelines are needed to fully integrate SLNB into standard clinical practice for vulvar cancer.